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titioners, psychiatrists, psychologists and social workers,
medications and ambulance services. Hospitalization
days were obtained from the Canadian Institute of Health
Information, and per diem costs were taken from the
London Health Sciences Centre in Ontario and from the
Psychiatric Specialty Hospital Cost Study. Ambulatory
visits were estimated from the Canadian Disease and
Therapeutic Index of Intercontinental Medical Statistics;
their unit costs correspond to weighted average costs
from 5 Canadian provinces. Medication costs were esti-
mated from the Compuscript of IMS. Productivity losses
were based on length of depressive episodes obtained
from the National Population Health Survey. Based on
the literature, we assumed that 1.8 working days/week
were lost during their episode. For the remaining working
days, productivity was assumed at 80%. Premature mor-
tality costs by suicide were estimated assuming that 60%
of suicides were caused by depression. Potential years of
life lost were multiplied by average earning taking into
account increase of labour productivity, employment rate
and a 5% discount rate.
RESULTS: The total cost of depression in Canada in
2000 was approximately $5.4 billions. Direct costs were
$2.1 billions or 39.5% of the burden. Indirect costs were
estimated at $3.2 billions. Mortality costs were $831 
millions, or 15.4%, and productivity losses $2.4 billions,
or 45.1%.
CONCLUSION: Based on these estimates, the burden of
depression in Canada is important. This sheds light on
the economic impact of this incapacitating mental disease.
PMH11
A SWEDISH PHARMACOECONOMIC




François C1, Henriksson F2,Toumi M1, Kornfeld A1
1Lundbeck SA, Paris, France; 2Stockholm School of Economics,
Stockholm, Sweden
OBJECTIVES: The purpose of this study is to assess 
the cost-effectiveness of escitalopram, a new selective
serotonin reuptake inhibitor (SSRI), versus citalopram,
ﬂuoxetine, and venlafaxine in Sweden.
METHODS: Cost-effective analysis is performed using 
a two-path decision analytic model with a 6-month
horizon. Patients start at the primary path, and are
referred to specialist care in the secondary care path. This
is typical of a GP/Psychiatrist setting. Model inputs
include drug-speciﬁc probabilities from comparative trial
data, published literature, and a clinical experts’ panel.
The primary outcome measure is ‘success’, deﬁned as
patients in remission 6 months after the start of treat-
ment. The model combines success rates and expected
costs to calculate the cost-effectiveness ratios. The 
estimated number of patient episodes during each drug
treatment (using IMS volume sales) are combined with
the average 6-month per-patient expected costs of treat-
ment (total and drug costs) to estimate the effect of the
introduction of escitalopram on the health care budget.
RESULTS: Treatment of Major Depressive Disorder with
escitalopram yielded a lower expected cost and greater
effectiveness compared to other SSRIs and SNRIs. The
expected success rate (remission) was 63.5% for esci-
talopram, compared to 57.2%, 57.0%, and 61.1% for
citalopram, ﬂuoxetine, and venlafaxine, respectively.
Average expected total medical costs per patient are
similar for escitalopram (SEK 15,670) and venlafaxine
(SEK 16,580), and somewhat higher for citalopram and
ﬂuoxetine (SEK 18,860 and 19,050 respectively). Bud-
getary impact shows that the increase in drug costs
(increase in Drug Budget estimated at SEK 44 million) is
more than offset by the decrease in other health care costs
(decrease in total Health Care Budget estimated at SEK
543 million).
CONCLUSIONS: Escitalopram is a cost-effective 
treatment alternative to citalopram, ﬂuoxetine, and ven-
lafaxine. The results of this study indicate that increased
utilisation of escitalopram might reduce health care costs
in Sweden.
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While several studies have measured the direct costs of
informal caregiving for Alzheimer’s patients, indirect
costs such as income losses to working caregivers and
productivity costs to their employers have received little
attention.
OBJECTIVES: This study estimates employment-related
costs of caregiving for Alzheimer’s patients and the effects
of the cholinesterase inhibitor, rivastigmine, on these
costs.
METHODS: Employment-related costs of informal
Alzheimer’s caregiving were imputed from several studies
on Alzheimer’s and caregiving, including ﬁndings from
the NAC/AARP survey of family caregivers. Published
employment-related costs, which applied to all caregivers
of the elderly, were made Alzheimer’s speciﬁc and differ-
entiated by disease stage. These estimates were linked to
clinical trial scores (Progressive Deterioration Scale) for
rivastigmine to estimate savings in employment-related
costs associated with this Alzheimer’s therapy.
RESULTS: Productivity costs to employers per working,
informal Alzheimer’s caregiver are $2,187 yearly, while
yearly income losses to working caregivers are $11,525.
Total productivity costs to employers are $1.89 billion
annually while total income losses to caregivers are $9.96
billion annually. Employment-related costs are highest 
for informal caregivers of Alzheimer’s patients in the
moderate disease stage because of a higher concentration
